ESLA
Estrella Immunopharma Inc.
NASDAQ: ESLA · HEALTHCARE · BIOTECHNOLOGY
$1.64
+11.56% today
Updated 2026-04-30
Market cap
$67.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.35
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Estrella Immunopharma Inc. (ESLA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+5.1%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+66.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-6.6%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-12.4%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-18 | $-0.01 | +85.7% | $1.11 | $1.10 | -0.9% |
| 2025-11-12 | $-0.13 | -85.7% | $2.51 | $2.20 | -12.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.07 | $-0.01 | +85.7% | — | — |
| 2025-09-30 | $-0.07 | $-0.13 | -85.7% | — | — |
| 2025-06-30 | $-0.12 | $-0.15 | -25.0% | — | — |
| 2025-03-31 | $-0.11 | $-0.06 | +45.5% | — | — |
| 2024-12-31 | $-0.12 | $-0.03 | +75.0% | — | — |
| 2024-09-30 | $-0.12 | $-0.09 | +25.0% | — | — |
| 2024-06-30 | — | $-0.11 | — | — | — |
| 2024-03-31 | — | $-0.01 | — | — | — |
| 2023-12-31 | — | $-0.03 | — | — | — |
| 2023-09-30 | — | $-1.78 | — | — | — |
| 2023-06-30 | — | $-0.03 | — | — | — |
| 2023-03-31 | — | $-0.03 | — | — | — |
Frequently asked questions
Has Estrella Immunopharma Inc. beaten earnings estimates?
Estrella Immunopharma Inc. has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +5.1% over the last 4 quarters.
How does ESLA stock react to earnings?
ESLA stock has moved an average of -6.6% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.